Characteristics of adverse event reporting of Xeljanz/Xeljanz XR, Olumiant, and Rinvoq to the US Food and Drug Administration

Autor:	Jingjing, Qian, Xiangzhong, Xue, John, Shannon
Rok vydání:	2022
Předmět:	Sulfonamides United States Food and Drug Administration Health Policy Pharmaceutical Science Pharmacy United States Arthritis Rheumatoid Pyrimidines Piperidines Purines Azetidines Humans Pyrazoles Female Heterocyclic Compounds 3-Ring
Zdroj:	Journal of Managed Care & Specialty Pharmacy. 28:1046-1052
ISSN:	2376-1032 2376-0540
DOI:	10.18553/jmcp.2022.28.9.1046
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62ac4f250290de7e31fcfde6f38edce7 https://doi.org/10.18553/jmcp.2022.28.9.1046 Zobrazit plný text záznamu